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While most cells of the central nervous system (CNS) express opioid 
receptors, the role of the endogenous opioid system in CNS development 
remains poorly understood.  
Identification of opioid functions during brain maturation is particularly 
crucial in light of the increasing trend in opioid abuse and the use of opioid drugs 
during pregnancy. New substitution therapies in pregnant opioid addicts include 
buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor 
antagonist.  However, while clinical studies demonstrated buprenorphine efficacy 
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in reducing neonatal withdrawal symptoms, there is a lack of information on the 
potential effects of this drug on brain development.   
Previous work from our laboratory has shown that perinatal exposure to 
buprenorphine induces dose-dependent alterations in rat brain myelination. 
These time-specific effects suggested that both therapeutic and supra-
therapeutic doses of the drug could alter the normal pattern of oligodendrocyte 
development. In support of this hypothesis, this thesis work has now found that 
buprenorphine exerts direct actions on the oligodendrocytes that are highly 
dependent on both the drug dose and stage of cell differentiation.  When 
exposed to buprenorphine, oligodendrocyte progenitors isolated from 3-day-old 
rat brain exhibit increased cell proliferation. In contrast, treatment of more mature 
oligodendrocytes obtained from 9-day-old rat brain induces dramatic dose-
specific effects on cell process network extension and membrane outgrowth. 
These later effects are accompanied by significant parallel changes in the 
expression of the four major splicing isoforms of myelin basic protein (MBP), a 
critical component of the myelin membrane and mature myelinating 
oligodendrocytes.  Furthermore, similar dose-specific effects on MBP expression 
are also elicited by methadone, a mu opioid receptor agonist already approved 
for the treatment of pregnant opioid addicts. Experiments with CTOP, a highly 
selective antagonist of the mu opioid receptor, further contribute to the idea that 
this receptor subtype plays an important function in controlling oligodendrocyte 
maturation. 
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These findings underscore the potential effects of opioid exposure during 
brain maturation and further indicate an important regulatory role of the 
endogenous opioid system in the control of oligodendrocyte development and 
myelination. 
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INTRODUCTION 
Epidemiological data show an increasing incidence of opioid abuse 
(Compton and Volkow, 2006), a critical problem among pregnant addicts. 
Surprisingly, little is known about the effects of these drugs on child 
development, although several clinical studies suggest that their use during 
pregnancy may interfere with the formation of the central nervous system (CNS). 
Infants exposed to opioids in utero exhibit reduced head circumference, 
decreased attention, altered fine motor coordination, and a greater risk of sudden 
infant death syndrome (Rosen and Johnson, 1982, Marcus et al., 1984, Kandall 
et al., 1993). In addition, longitudinal studies found that these children showed 
heightened activity, impulsivity, and reduced attention span, suggesting 
underlying neurological problems (Hutchings, 1982). However, the effects of 
perinatal exposure to opioids on brain development are difficult to assess 
because behavioral and cognitive outcomes in children are known to be highly 
influenced by environmental, educational, and lifestyle factors (Ornoy et al., 
2001).  
The current FDA approved standard treatment for opioid addiction during 
pregnancy is substitution therapy with methadone, even though this mu opioid 
receptor agonist has been linked to neonatal abstinence syndrome upon 
discontinuation (Fischer et al., 2006, Lejeune et al., 2006). One alternative 
possibility is the use of buprenorphine. This mu partial agonist and kappa 
antagonist has been approved to treat opioid-dependent adults in the United 
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States and is also being used experimentally in pregnant addicts in this and 
several other countries. Clinical trials indicate that buprenorphine is effective in 
the prevention of “street opioid” abuse by pregnant addicts as well as reducing 
the incidence and severity of neonatal abstinence syndrome (Jones et al., 2005, 
Ebner and Wiedmann, 2006). However, as indicated above, not much is known 
about the potential effects of these treatments on the developing CNS. 
The brain is most vulnerable to insults during development when critical 
periods of network establishment and refinement are underway. Recent studies 
suggest that a major factor in the coordination of these events is the endogenous 
opioid system. Both neurons and glia express opioid receptors and endogenous 
opioid peptides in a developmentally controlled manner (Wu et al., 1997, Ikeda et 
al., 1998, Knapp et al., 1998, Leslie et al., 1998, Miller and Azmitia, 1999, Kivell 
et al., 2004). In this regard, perinatal exposure of rats to buprenorphine has been 
shown to delay the generation of cholinergic neurons (Robinson, 2002) and to 
reduce the expression of nerve growth factor in the striatum (Wu et al., 2001), 
underscoring the importance of further research on the actions of this drug in 
CNS development. 
 Interestingly, previous work from our laboratory has shown that 
buprenorphine affects the formation of myelin (Sanchez et al., 2008), the 
multilamellar membrane that insulates axons allowing the rapid saltatory 
conduction of nerve impulses. In the CNS, the myelin membrane is produced by 
oligodendrocytes, a type of glial cell, which is the center of these studies and will 
be described in detail in the following sections of this thesis. The synthesis of 
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myelin is under control of multiple growth factors and hormonal signals as well as 
cell-cell interactions, making this a particularly vulnerable process during CNS 
development. The observed effects of buprenorphine on myelination beg further 
investigation, as the roles of opioid receptors in oligodendrocyte development 
and in vivo myelination are unknown.  
This work investigates the direct effects of opioids on developing 
oligodendrocytes in vitro. Characterizing these specific effects will help to further 
understand the in vivo role of the endogenous opioid system in controlling 
myelination as well as provide important clues for the development of therapeutic 
interventions for pregnant opioid addicts.  
First, a background of opioids and glia will be given before we investigate 
their coordinated effects on oligodendrocyte development and function. 
   
OPIOIDS   
Opioids comprise a family of drugs that has long been used to relieve 
various types of pain. Opiates were originally defined as derivatives of the opium 
poppy (papaver somniferum).  However, the modern term “opioids” 
encompasses opiates as well as synthetic and endogenous molecules, all of 
which are able to interact with opioid receptors. Today, these compounds are 
widely used for their analgesic properties as well as their inhibitory effects on the 
digestive system.  
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Opioids have been used medicinally for thousands of years. The use of 
opium for pain management and dysentery treatment existed in antiquity, but did 
not become widespread until the mid-19th century.  The global opium trade 
originated in the Middle East and was facilitated by the imperial campaigns of the 
British Empire. Soon, opium use spread to the Far East as well as Western 
Europe. Opioids had previously been available in the United States, but at the 
turn of the century their use expanded dramatically. Heroin was widely used to 
relieve cough, as well as a range of maladies from digestive problems to 
menstrual pain. However, these substances are characterized by their high 
potential for abuse, resulting in serious clinical manifestations and making users 
vulnerable to severe withdrawal upon cessation. As they became readily 
available, the incidence of opiate abuse rose. By 1914, the US government 
acknowledged the growing problem and brought opioids under federal regulation 
by passing the Harrison Act (Acker, 2002). Presently, opioids are clinically 
available by prescription only. Yet opioid abuse remains a problem worldwide.  
 
Physiological Effects of Opioids 
Opioids are the most effective drugs known for pain relief. At therapeutic 
doses, they successfully suppress pain with a minimal effect on other sensations. 
Opioid analgesia is specific to ‘second pain’: the dull ache after noxious stimulus, 
or ‘first pain’ (Cooper et al., 1986). This may explain the evolutionary significance 
of the endogenous opioid system—dulling second pain does not hinder 
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perception of future noxious stimuli. Opioids have also been shown to reduce 
emotional pain, which is a major factor in their high potential for addiction.  
These drugs cause marked physiological changes when consumed at 
analgesic doses. Decreased body temperature and pituitary function, respiratory 
depression, pupil constriction, suppressed cough reflex, nausea, decreased 
gastrointestinal secretions and motility, and suppression of the immune system 
are all observed. In neurons, opioids presynaptically inhibit the release of small 
nociceptors via the inhibition of calcium channels (Taddese et al., 1995). 
 
Opioid Subtypes  
Naturally Occurring Opiates 
 The naturally occurring opiates are alkaloids derived from the papaver 
somniferum plant. Morphine is the predominant type, but codeine and thebaine 
can also be derived from the plant (Martin, 1967). 
Synthetic Opioids 
 Synthetic opioids are the largest subtype and constitute the majority of 
molecules within this group that are used for pharmaceutical purposes (Portenoy, 
1993). These substances have molecular structures analogous to those of 
naturally occurring opioid alkaloids. Examples include diacetylmorphine (heroin), 
hydrocodeine, oxycodone, fentanyl, methadone, and buprenorphine. Along with 
morphine, many synthetic derivatives are used clinically for pain management. 
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Buprenorphine and methadone, notably, are used to treat opioid addiction by 
mitigating withdrawal symptoms through replacement therapy (Figure 1).  These 
two drugs will be described in more detail in following sections of this thesis as 
their administration to pregnant opioid addicts has the potential of affecting 
crucial steps along brain development. 
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Figure 1. The molecular structures of buprenorphine and methadone. These 
synthetic opioids are commonly used in replacement therapy. 
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Endogenous Opioids 
Interestingly, the human body produces endogenous opioid peptides that 
were discovered as a result of initial studies investigating exogenous opioid 
actions and the role of different opioid receptors.  Many of the original studies 
used high-affinity alkaloids to identify opioid receptor types. Morphine was used 
to identify the mu receptor, ketocyclazocine for the kappa receptor (Lord et al., 
1977). However, a stimulation-induced analgesia was observed in animals that 
could be reversed with the administration of naloxone, a known opioid receptor 
antagonist (Mayer et al., 1971). The first two peptide candidates for mediating 
this response were methionine- and leucine-enkephalin, endogenous peptides 
consisting of five amino acid residues (Waterfield et al., 1976). Shortly thereafter, 
β-endorphin and dynorphin were isolated. The enkephalins, endorphins, and 
dynorphins make up the three distinct groups of endogenous opioid peptides.  
The constituents of these three groups differentially bind the mu, delta, and 
kappa opioid receptors with varying affinity. The ORL-1 receptor only binds the 
endogenous peptides nociceptin and orphanin FQ (Meunier et al., 1995, 
Reinscheid et al., 1995).  
 
Opioid Receptors 
All opioids bind to at least one type of opioid receptor. This family of 
receptors is comprised of the mu opioid receptor, the kappa opioid receptor, the 
delta opioid receptor, and the opioid receptor-like 1 receptor (ORL-1). This 
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nomenclature was derived from radiolabeled ligand affinity studies. For example: 
the mu receptor was defined and characterized by its high affinity for morphine. 
These studies revealed stereospecific, saturatable binding kinetics (Pert et al., 
1973), along with the differential distribution of mu, delta, and kappa in the brain 
with a high concentration present in areas relevant to pain, including the 
periaqueductal grey, medial thalamus, and amygdala (Hiller et al., 1973, Kuhar et 
al., 1973, Pert et al., 1976).  ORL-1 was discovered decades later through 
sequence homology studies. Like the other receptors, it was cloned and shown 
to match the endogenous receptor. Originally, it was named the N/OFQ receptor 
for its endogenous ligands: nociceptin and oprhanin FQ (Butour et al., 1997). It 
differs from mu, delta, and kappa receptors by its negligible response to 
naloxone—a potent antagonist to the three other receptors. In addition, ORL-1 
does not bind any of the other endogenous opioid peptides. 
The mu, delta, and kappa opioid receptors exhibit both high structural and 
functional homology. These molecules are G-protein coupled receptors (GPCR) 
with seven transmembrane domains spanning the phospholipid bilayer. The 
receptor is coupled to a heterotrimeric G-protein that acts as the transducer 
between receptor and the eventual effector response. These G-proteins are 
composed of three subunits whose activity is regulated by allosteric interaction 
with guanosine triphosphate (GTP) and guanosine diphosphate (GDP). When 
bound by an agonist, opioid receptors inhibit adenylyl cyclase activity through 
activation of the Gi/G0 G-protein. These G-proteins can also affect phospholipase 
C, mitogen-activated protein kinase (MAPK), and ion channel activity. Gi/G0 
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appears to be the G-protein most prominently involved in these primary 
transduction mechanisms, but opioid receptors have also been linked to other G-
proteins that mediate secondary transduction mechanisms (e.g. Gq, G11, G12, 
G13, and G16) (Lee et al., 1998, Ho et al., 2002). These primary and secondary 
effects alter levels of second messengers like cyclic adenosine monophosphate 
(cAMP), diacylglycerol (DAG), and inositol triphosphate (IP3), signaling molecules 
which can regulate the expression and activation of various kinases and 
transcription factors and eventually cause changes in gene regulation. The mu, 
delta, and kappa receptors all have constitutive levels of activity, so responses to 
ligand binding are modulatory as opposed to binary.  
GPCRs are subject to desensitization and endocytosis with chronic opioid 
use. β-arrestin is recruited to the receptor after it is phosphorylated by G protein 
receptor kinase and decouples the receptor from the G protein. Unlike other 
models of chronic receptor activation, opioid receptor levels do not decrease 
dramatically over time. One hypothesis is that the GPCR becomes dissociated 
from its downstream effectors and therefore is less effective in inhibiting adenylyl 
cyclase (Christie et al., 1987).  
 
GLIAL CELLS 
The neuronal doctrine has dictated the study of brain function and brought 
about our current understanding of the nervous system. This dogma proffers that 
neurons and the synapses adjoining their networks are the primary units of the 
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nervous system structure and function. In recent years, however, this view has 
been borne out as incomplete. Glial cells were characterized by Virchow as 
“nervenkitt” (nerve glue) upon their discovery, but they are increasingly 
implicated in signaling, development, plasticity, and other functional aspects of 
the brain. Recent evidence suggests that glial networks act in concert with 
neurons to refine and control the nervous system.  
 
Glia Characteristics  
 Glia consist of five cell types: astroglia, microglia, oligodendrocytes, 
ependymal cells of the CNS, and the Schwann cells of the peripheral nervous 
system (PNS). Each of these cell groups possesses an array of functions which 
are integral to nervous system physiology. Along with neurons, glial types 
constitute the main categories of cells in the CNS. Neurons differ from glia in 
their ability to conduct action potentials. However, the inability of glia to 
propagate these all-or-none electrical signals does not designate them as static 
entities; rather, they refine circuits by limiting and directing electrical propagation.  
 Surprisingly, glia are the predominant cell type while neurons account for 
only 20%-40% of all cells in the CNS. The macroglia, of ectodermal origin, are 
comprised of astrocytes (60-80%), ependymal cells (5%), and oligodendrocytes 
(5%-10%). Microglia originate from the mesoderm and under normal non-
inflammatory conditions they make up 10% of the CNS glia.  
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Glial morphology and distribution was thoroughly described in the 19th 
century by histologists Camillo Golgi, Santiago Ramón y Cajal, and Pio Del Rio 
Hortega. Yet, investigation of their functional importance was not conducted until 
recent decades. Glial coupling and networks were first observed in the 1960’s 
(Kuffler and Nicholls, 1966, Brightman and Reese, 1969). However, technological 
improvements were necessary for advancing the study of glial function, and, in 
1984, receptors for the neurotransmitters glutamate and gamma-aminobutyric 
acid (GABA) were discovered in astrocytes and oligodendrocytes (Bowman and 
Kimelberg, 1984, Kettenmann et al., 1984a, Kettenmann et al., 1984b). In recent 
years, glia have shed their label as the mortar of the CNS and proven to play a 
variety of functional roles. Astrocytes are known to express multiple receptors 
and enzymatic systems whose main functions are to maintain nervous system 
homeostasis and to limit neurotransmitter availability. These cells are also 
implicated in the induction and formation of the blood brain barrier and 
developmental synaptogenesis (Barker and Ullian, 2010, Giaume et al., 2010, 
Christopherson et al., 2005). 
On the other hand, oligodendrocytes are responsible for making the 
myelin membrane in the CNS.   Schwann cells represent their counterparts in the 
PNS. Oligodendrocytes are the center of these studies and therefore, they will be 
described in greater detail in the following sections. 
Importantly, The ability of both astrocytes and oligodendrocytes to 
respond to neurotransmitters (Karadottir et al., 2005); together with the newly 
established presence of glial networks (Verkhratsky et al., 2009), has profoundly 
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implicated glia in current neurobiological studies, challenging many preconceived 
ideas on the organization and functioning of the CNS.  
 
The Myelin Membrane 
Myelin Structure 
 Myelin is a specialized multilamellar structure that ensheaths axons in the 
vertebrate nervous system. It is a three-dimensional structure formed by the 
extension and concentric wrapping of the oligodendroglial membrane, remaining 
continuous with the oligodendrocyte. A single oligodendrocyte can myelinate 10-
30 axons simultaneously and multiple oligodendrocytes are responsible for 
generating the different myelin internodes along a single axon, resulting in a 
highly intricate glial-neuronal network (Baumann and Pham-Dinh, 2001).  
A periodicity to myelin exists; it is generated along the axons as 150-200 
nanometer-long longitudinal segments called internodes (Butt and Ransom, 
1989). These internodes are flanked by the nodes of Ranvier: axonal areas 
lacking myelin but with an increased density of ion channels. As discussed later, 
this periodic distribution of ion channels is determined by the presence of 
internodes, and together with the insulating properties of myelin, is the basis for 
the rapid saltatory conduction of electrical signals—the impulse jumps from node 
to node.   
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 Cross sections of myelinated axons visualized by electron microscopy 
(Figure 2) show that myelin appears as a sequence of dark and less dark lines 
separated by lighter zones. The dark line—known as the major period line—is 
formed by the fusion of inner cytosolic surfaces of the oligodendrocyte 
membrane. On the other hand, the lighter line is the intraperiod or minor dense 
line, formed by the compaction of the membrane’s outer leaflets. Uncompacted 
areas in the myelin internode are believed to be essential for cellular transport 
and myelin maintenance. Because myelin is a dynamic structure its components 
must constantly be replaced to account for normal membrane turnover. These 
areas of cytoplasm are known as paranodal loops and contain mitochondria, free 
polysomes, and smooth endoplasmic reticulum for protein and lipid synthesis. 
Paranodal loops tend to be located near nodal regions and form transverse 
bands with the periaxonal membrane, which strengthen the connection between 
the axon and paranode (Ichimura and Ellisman, 1991). This is markedly different 
from myelin in the internodal region, which is separated from the periaxonal 
space by an extracellular gap.  
 
The Role of Myelin in Nerve Transmission and Axonal Integrity 
 In unmyelinated nerve fibers, conduction velocity is mainly dependent on 
axonal caliber. In contrast, myelinated fibers allow for rapid conduction velocity 
and transmission fidelity without a corresponding increase in axonal caliber. This 
is achieved by a fundamental difference in conduction mechanism between both 
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types of fibers. In unmyelinated fibers, a uniform distribution of ion channels 
throughout the axolemma results in local circuits propagating depolarization in a 
continuous manner along the axon. By contrast, myelinated axons only expose 
the axonal membrane to the extracellular space at nodal regions. Depolarization 
cannot move continuously along the axon due to the high membrane resistance 
and absence of ion channels in myelinated internodes. Therefore, depolarization 
can only occur at nodes where ion channels are exposed. The impulse jumps 
from node to node. This is known as ‘saltatory’ conduction (Figure 3).  
 Furthermore, several lines of evidence indicate that myelin is also a key 
factor in axonal development. It has been shown that myelination can regulate 
axonal caliber in the optic nerve as well as neurofilament spacing and 
phosphorylation, both of which control axonal radial growth (Hsieh et al., 1994, 
Sanchez et al., 1996). Moreover, several lines of evidence have shown that 
myelination also exerts control over the distribution of the voltage-gated ion 
channels responsible for impulse conduction. Different studies have shown that 
the myelin membrane functions as a barrier that limits the lateral movement of 
ion channels in the axolemma, restricting the localization of voltage-gated sodium 
channels to the nodes of Ranvier while fast voltage-gated potassium channels 
are concentrated in the juxtaparanode (Rasband and Trimmer, 2001, Poliak and 
Peles, 2003, Rosenbluth, 2009). 
 In mature vertebrates, myelin also functions as an inhibitor of neurite 
outgrowth (Domeniconi et al., 2002). By dampening plasticity, myelin may act to 
refine late-developing tracts and preserve established myelinated regions. 
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Moreover, evidence from demyelinating diseases like multiple sclerosis suggest 
that both oligodendrocyte and myelin play an important role in axonal protection 
and survival (Nave and Trapp, 2008). 
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Figure 2. The myelin sheath forms axonal domains which are essential for 
impulse conduction. (A) An electron micrograph from a longitudinal section 
from rat spinal dorsal root nerve showing the node of Ranvier flanked by 
internodal segments insulated by layers of compact myelin. Each layer of myelin 
terminates in a series of loops adjacent to the node of Ranvier (the paranodal 
loops) (B) Three axonal domains are defined by axon interactions with 
myelinating glia: the Na+ channel-enriched node of Ranvier, the adjacent 
paranode where the loops of myelin adhere to the axon through cell-adhesion 
molecules linked to the axonal cytoskeleton, the juxtaparanode which contains K+ 
channels and the internode sealed by compacted layers of myelin membrane to 
restrict transmembrane ion currents to the nodal region. Modified from Fields, 
RD, Trends Neuroscience, 2008
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Figure 3. Comparison between conduction in a myelinated axon versus an 
unmyelinated axon. Arrows show the flow of action potential in local circuits into 
the active region of the membrane. (A) In unmyelinated fibers, the current flows 
throughout the length of the axon in contrast to (B) myelinated fibers where the 
current jumps between adjacent nodes resulting in saltatory conduction. Modified 
from Basic Neurochemistry, edited by Siegel, Albers, Brady and Price, Elsevier, 
2006.
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Myelin Composition 
Myelin is composed of approximately 70% lipid and about 30 % protein, 
resulting in a highly hydrophobic membrane. This elevated degree of 
hydrophobicity and the compact multilamellar structure of myelin are responsible 
for its high insulating capacity.  
Although no single lipid is unique to myelin or oligodendrocytes, the 
proportions of the various lipids are exclusive characteristics. When compared 
with other membranes and cells, both myelin and oligodendrocytes are highly 
enriched with glycosphingolipids (e.g. galactosylceramides) and their sulfated 
derivates: sulfatides (e.g. sulfogalactosylceramides) which, combined, make up 
20 percent of the lipids in myelin (Morell et al., 1973).  
 In contrast to the lipids, there are characteristic proteins unique to myelin 
and oligodendrocytes. Myelin basic protein (MBP) and proteolipid protein (PLP) 
represent about 80 percent of the total proteins present in myelin (Morell et al., 
1973).  
MBP exists in 3-4 major isoforms, depending on species, ranging in 
molecular weight from 14 to 21.5 kDa. Altogether, MBPs constitute about 30 
percent of the myelin proteins (Boggs, 2006). The various MBPs are generated 
by alternative splicing of a single gene, allowing for precise biological control of 
protein isoform expression along development (de Ferra et al., 1985, 
Campagnoni, 1988). As further discussed in following chapters of this thesis, the 
differential localization of MBP isoforms in oligodendrocytes and myelin suggest 
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that some of these proteins may play a role in cell differentiation while others are 
mainly structural components of the myelin membrane (Pedraza et al., 1997). In 
this regard, studies in MBP-deficient mice have evidenced that MBP is an 
essential factor in myelin compaction (Readhead et al., 1987).  
The other major myelin protein, PLP, exists in two isoforms (25 & 20 kDa), 
also originating from alternative splicing of a single gene (Nave et al., 1987). PLP 
may be acylated on cysteine residues, making it a hydrophobic proteolipid 
complex. Other myelin and oligodendroglial proteins include the enzyme 2',3'-
cyclic nucleotide 3'-phosphodiesterase (CNPase) (Wolfgram, 1966), myelin-
associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG). 
Antibodies raised against all of these proteins are frequently used as tools to 
study myelin formation and oligodendrocyte development.  
Myelination: A Complex Developmental Process 
 The process of myelination in the developing brain is observed as a well-
regulated event, conserved temporally and anatomically, yet the precise signals 
and regulatory mechanisms are still poorly understood. Oligodendrocyte 
migration and membrane synthesis must be tightly controlled to achieve proper 
myelination in the CNS. Given that oligodendrocytes only myelinate axons, it is 
evident that specific mechanisms of communication between neurons and 
oligodendrocytes must exist. It has been observed that electrical activity along 
the axon is essential for proper myelination, but specific molecular interactions 
between the axon and oligodendrocyte remain unclear (Tauber et al., 1980). The 
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expression of NMDA receptors in oligodendrocytes suggests that Ca2+ signaling 
in these glial cells is activated by axonal signals. Further support for signaling 
from neurons to myelinating glia is supported by previous findings from this 
laboratory indicating that oligodendrocytes respond to different neurotransmitters 
activating CREB (Sato-Bigbee et al., 1999), a transcription factor that controls 
proliferation, survival, and myelin protein expression in these cells (Afshari et al., 
2001, Saini et al., 2004, Saini et al., 2005).  In addition, the spatial coordination 
between neurons and myelinating oligodendrocytes may be subjected to control 
by astrocytes (Meyer-Franke et al., 1999).  
Oligodendrocyte Development 
 As described previously, the formation of myelin during CNS development 
requires the integration of multiple signals and cells. In order to decipher the 
complex concert of events that result in proper myelination, it is critical to 
understand the development of oligodendrocytes. Mitotically active cells in the 
brain that are immunopositive for a chondroitin sulfate proteoglycan—NG2—are 
the progenitor cell population which gives rise to oligodendrocytes (Nishiyama et 
al., 1996). Different studies have indicated that the NG2+ population may be 
multipotent with the ability to generate neurons and astrocytes, but 90 percent of 
its progeny is oligodendrocytes.  
 An oligodendrocyte progenitor cell will arise from an NG2+ cell in 
ventricular zones of the brain and spinal cord (Luskin et al., 1988, Price and 
Thurlow, 1988). These oligodendrocyte progenitors are migratory and mitotically 
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active. They are characterized by the expression of certain transcription factors, 
including Olig1, Olig2, SOX10, and Nkx2.2 (Baumann and Pham-Dinh, 2001). 
Morphologically, oligodendrocyte progenitors appear as cells with a simple soma 
with one or two emerging polar processes.  
 Once the oligodendrocyte progenitor has migrated to the proper site, local 
growth factors drive its continuing maturation. Thyroid hormone (T3) is a terminal 
differentiation signal to the oligodendrocyte progenitor, halting its mitotic activity 
and effectively inducing its conversion to a pre-oligodendrocyte (Almazan et al., 
1985, Barres et al., 1994). These pre-oligodendrocytes can be identified by their 
expression of sulfatides, recognized by the O4 antibody (Bansal et al., 1989). 
The onset of CNPase expression is another hallmark of a developing 
oligodendrocyte. As they mature, pre-oligodendrocytes begin to form more 
complex networks of cells processes. Finally, the expression of MBP, PLP, MAG, 
and other characteristic myelin proteins will be observed when the cells develop 
into fully differentiated oligodendrocytes (Figure 4). This developmental 
sequence can be replicated in vitro, but proper myelin formation requires the 
presence of neurons and axon-glial interaction.  
 Such a dynamic process is under tight, yet fragile biological control. Many 
pathologies involving demyelination or dysmyelination represent an aberration in 
oligodendrocyte development. A greater understanding of the precise 
developmental controls will certainly reveal therapeutic targets for these 
diseases.  
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Figure 4. Stages in the development of oligodendrocytes. Each stage of 
oligodendrocyte differentiation is characterized by the expression of specific 
markers. Early progenitors are bipolar cells that can be labeled with the A2B5 
antibody and express the PDGF-α receptor and the NG2 chondroitin sulfate 
proteoglycan. The next stage is represented by committed oligodendrocytes, 
multipolar cells that react with O4 antibody. The expression of the myelin 
proteins, including MBP and PLP, marks the final stage of differentiation.
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Oligodendrocyte development must remain under precise biological 
control to ensure temporal and spatial fidelity. As indicated before, myelin has 
been shown to control both axonal radial growth and extension as well as to 
refine neuronal networks. Thus, understanding the factors controlling 
oligodendrocyte maturation and function could reveal therapeutic targets across 
the broad functionality of these cells.  
 The discovery of opioid receptors in oligodendrocytes raised questions 
about the potential effects of the endogenous opioid peptides on oligodendrocyte 
development. Work by Knapp et al. showed that oligodendrocytes express mu, 
delta, and kappa opioid receptors in a developmentally regulated manner. 
Moreover, oligodendrocytes also express their own endogenous opioids as levels 
of neuropeptide zymogens (proenkephalin and prodynorphin) were measured in 
those in vitro studies (Knapp et al., 2001).  
 Interestingly, activation of mu opioid receptor in oligodendrocyte 
progenitors resulted in increased proliferation. When the kappa opioid receptor 
was blocked, oligodendrocyte progenitors showed increased morphological 
differentiation whereas mature oligodendrocytes showed increased cell death.  
Additional work has connected the kappa opioid receptor to pathology in 
the jimpy mouse, in which mutation in the myelin PLP gene causes 
oligodendrocyte death and severe CNS hypomyelination. These PLP deficient 
mice were shown to have a concomitant loss of the kappa opioid receptor in 
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oligodendrocytes. This 90% reduction is specific to the kappa opioid receptor and 
does not affect any other opioid receptors, suggesting that the kappa opioid 
receptor may be part of essential survival pathways. Taken together, these 
results suggest that endogenous opioids may serve as autocrine/ paracrine 
survival signals in oligodendrocyte development (Knapp et al., 2009). Control of 
opioid receptor levels as well as endogenous opioid expression may be essential 
to proper development and myelination. 
 In support of a crucial role of the opioid system in controlling myelin 
formation, recent in vivo studies from our laboratory have shown that perinatal 
exposure to buprenorphine affects myelination in the developing rat brain 
(Sanchez et al., 2008).  
 As described before, the mu partial agonist and kappa antagonist 
buprenorphine is currently used in clinical trials for pregnant opioid addicts. This 
drug appears to effectively prevent “street opioid” abuse by pregnant addicts as 
well as to decrease the incidence of neonatal abstinence syndrome.  However, 
the effects of buprenorphine on child brain development remain unknown.  
 In our previous experiments, pregnant rats were implanted with 
minipumps to deliver buprenorphine at 0.3 or 1 mg/kg/day. While the lower dose 
is within the therapeutic levels of buprenorphine given to humans during 
gestation, 1 mg/kg/day correspond to a supra-therapeutic or abuse dose of the 
drug.  Buprenorphine is known to cross into breast milk and thus, drug exposure 
via maternal milk was continued until the time of sacrifice or until weaning at 21 
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days postnatal. Analysis of the pup brains indicated that exposure to low, 
therapeutic doses of buprenorphine resulted in accelerated and increased 
expression of all MBP isoforms from postnatal day 12 to 26, corresponding to the 
normal period of rapid myelination in the developing brain. Conversely, perinatal 
exposure to the higher dose of buprenorphine resulted in delayed expression of 
all MBP isoforms, although levels recovered to normal values by postnatal day 
26. Exposure to this elevated dose also resulted in a 25% decrease in the 
number of myelinated axons of the corpus callosum, a heavy myelinated 
structure that connects both cerebral hemispheres. These data are suggestive of 
a dose-specific mechanism controlling oligodendrocyte maturation and 
myelination in the developing brain.  
Interestingly, analysis of the corpus callosum also indicated that, 
regardless of the dose, myelinated axons in pups exposed to buprenorphine 
exhibited increased axonal caliber accompanied by disproportionately thinner 
myelin sheath. Since the caliber of unmyelinated axons was not affected, this 
alteration of the normal myelin thickness/axonal diameter ratio suggests that 
disruption of endogenous opioid signaling by buprenorphine exposure alters 
oligodendroglial-neuronal interactions which are crucial to the coordination of 
myelin formation with radial axonal growth (Sanchez et al., 2008).  
It is apparent that neuron-glia interaction is critical to proper myelination, 
but these data beg the question: where and how are opioids acting to control 
myelination in the developing brain?  
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The presence of opioid receptors on neurons and glial cells confounds any 
conclusions drawn from these data, so further studies are required to clarify any 
direct effects of buprenorphine on developing oligodendrocytes.  To address this 
problem, experiments in this thesis investigated the potential direct effects of 
buprenorphine on cultured oligodendrocytes. The results indicated that 
buprenorphine indeed exerts direct dose-dependent effects that are highly 
specific for different stages of oligodendrocyte development.  Moreover, similar 
effects were also observed for methadone, further stressing the need for detailed 
studies on the effects of opioid addiction treatments on brain development. 
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MATERIALS AND METHODS 
Materials: Percoll, bovine pancreas DNAse and papain for cell isolation as well 
as all cell culture medium components were purchased from Sigma-Aldrich (St. 
Louis, MO). Dulbecco’s modified Eagle’s medium/ Ham’s F-12 (DMEM/F-12) 
(1:1) medium was obtained from Invitrogen (Grand Island, NY). Reduced growth 
factor Matrigel was from Becton Dickinson (Franklin Lakes, NJ). Buprenorphine, 
methadone, and the mu opioid receptor antagonist CTOP were purchased from 
Sigma-Aldrich (St. Louis, MO). All gel electrophoresis reagents and supplies 
were purchased from Bio-Rad Laboratories (Hercules, CA). The mouse anti-β-
actin and rat anti-MBP (82-87 region) monoclonal antibodies were from Sigma-
Aldrich and Millipore Corporation (Temecula, CA), respectively. The mouse O4 
monoclonal antibody was kindly provided by Dr. Rashmi Bansal (University of 
Connecticut, Farmington, CT). Super Signal West Dura reagent was obtained 
from Pierce (Rockford, IL). Methyl-[3H] thymidine (specific activity 75Ci/mmol) 
was from Amersham (Piscataway, NJ).All appropriate secondary antibodies were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  
 
Isolation and culture of oligodendrocytes: Timed-pregnant Sprague-
Dawley rats were provided by Harlan Laboratories (Frederick, MD). 
Oligodendrocytes at different stages of development were directly isolated from 
3- to 9-day-old rat brains as described previously (Colello and Sato-Bigbee, 
2001) with minor modifications. For this, the brains were rapidly dissected out, 
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transferred to ice, and the meninges and main blood vessels removed by rolling 
the tissue on sterile filter paper. After mincing into 1-2 mm pieces, the tissue was 
incubated for 25 min. at 37oC in the presence of 1 unit/ml papain and 0.01 mg/ml 
DNAse. Following incubation, the tissue was extensively washed and a total cell 
suspension prepared by forced filtration through a 75 µm pore size nylon mesh. 
The resulting suspension was centrifuged for 15 min at 30,000 x g in an isotonic 
self-generated Percoll gradient.  The band enriched in oligodendrocytes was then 
subjected to differential adhesion on tissue culture-treated Petri dishes to 
eliminate microglial cells and residual astrocytes. The floating oligodendrocytes 
were then plated in 48-well plates (Falcon) (for western blot analysis) or on 
10mm cover slips in 24-well plates (for immunocytochemistry) previously coated 
with 12.5 µL/well reduced growth factor-Matrigel extracellular matrix. Prior to use, 
the cells were maintained overnight in chemically defined medium (CDM) 
(DMEM) /F-12) supplemented with 1 mg/mL fatty acid-free bovine serum 
albumin, 50 µg/mL transferrin, 5 µg/mL insulin, 30 nM sodium selenite, 0.11 
mg/mL sodium pyruvate, 10 nM biotin, 20 nM progesterone, 100 µM putrescine, 
15 nM triiodothyronine. Astroglial contamination of these cultures, as assessed 
by glial fibrillary acid protein staining, was less than 5%. Animal use and isolation 
of oligodendrocytes were conducted in accordance with the guidelines from the 
National Institutes of Health and approved by the Virginia Commonwealth 
University Animal Care and Use Committee. 
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Western blot analysis: Pre-oligodendrocyte cultures containing equivalent 
numbers of cells per well were lysed in 80 µL of 60 mM Tris-HCl buffer (pH 6.8) 
containing 10% glycerol, 2% sodium dodecyl sulfate (SDS), and 5% 2-
mercaptoethanol. 10 µL samples were subjected to SDS-polyacrylamide gel 
electrophoresis in 15% acrylamide and the proteins were electrotransferred to 
nitrocellulose. The membranes were then subjected to immunoblot analysis as 
previously reported (Saini et al., 2005), with minor modifications. Nonspecific 
antibody binding to the blots was blocked by incubation in 10 mM Na2HPO4, 2.7 
mM KCl and 137 mM NaCl, pH 7.4, (PBS) containing 3% nonfat dry milk and 
0.05% Tween-20 (blocking solution), for 1 hour at room temperature. Blots were 
then incubated overnight with anti-Myelin Basic Protein (dil. 1:100), an antibody 
that reacts with all 4 major MBP isoforms. β-Actin levels detected with anti-β-
actin antibody (dil. 1:2,000) were used as loading controls. After extensive rinsing 
with PBS, blots were incubated for 30 min in blocking solution, followed by 
incubation with the appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody for 2 hours. All antibodies were diluted in blocking buffer. 
After two 5-min rinses in PBS containing 0.05% Tween-20 and four 10-min rinses 
in PBS, the immunoreactive bands were detected by chemiluminescence with 
Super Signal West Dura reagent. The relative amount of immunoreactive protein 
in each band was determined by scanning densitometric analysis of the X-ray 
films using the NIH Image J program. After quantification of the bands, values 
were divided by β-actin levels to correct for loading differences. 
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[3H]Thymidine incorporation: After isolation, oligodendrocyte progenitors 
isolated from 3-day-old rat brain were plated on 48- well plates previously coated 
with 12.5 µL/well reduced growth factor Matrigel and maintained overnight in 
CDM. The next day, the medium was replaced with CDM containing 3 µCi/mL 
[3H]thymidine, in the presence or absence of different concentrations of 
buprenorphine or methadone. After 24 hours, the cultures were washed three 
times with ice-cold PBS, followed by incubation with 20% trichloroacetic acid 
(TCA) for 30 minutes at 4ºC. After three 15 minute washes with 10% TCA, the 
cells were solubilized by incubation with 70% formic acid at 37°C for 1 hour. 
Aliquots were then used to determine the radioactivity by liquid scintillation 
counting. 
 
 
 Immunocytochemistry: Pre-oligodendrocytes were plated in 24-well plates 
(Fisher) on 10mm cover slips coated with 12.5 µL/well reduced growth factor 
Matrigel and maintained overnight in CDM. The next day, the medium was 
replaced with CDM alone or supplemented with buprenorphine. The medium was 
replaced every 48 hours. After 4 days of incubation, the cells were fixed in 4% 
paraformaldehyde and immunocytochemistry was carried out as previously 
reported (Sato-Bigbee et al., 1999). Non-specific antibody binding was blocked 
by incubation of the cells for 1 hour in PBS containing 5% non-fat dry milk, 0.05% 
Tween-20, and 0.5% normal goat serum (blocking solution). The cells were then 
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incubated overnight with the O4 antibody (dil.1:3) and MBP antibody (dil. 1:10) in 
blocking solution. After several washes in PBS, the cells were incubated for 30 
min in blocking solution and for 2 hours with Alexa 488-conjugated anti- mouse 
IgM (dil. 1:250) or Texas Red-conjugated anti-rat IgM (dil. 1:150). The cultures 
were analyzed using a Nikon Eclipse 800M fluorescence microscope. 
 
Statistical Analysis: Statistical analysis was performed by one-way analysis 
of variance using the GraphPad Prism program. Differences between results 
were considered statistically significant when p values were <0.05. 
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RESULTS 
As described before, our previous studies indicated that perinatal 
exposure to buprenorphine causes dose-specific and developmentally dependent 
effects on brain myelination. Elevated levels of MBP expression were observed 
at all studied ages in the brains of pups exposed to therapeutic drug doses. In 
contrast, treatment with a supra-therapeutic dose was accompanied by delayed 
MBP expression and reduced number of myelinated axons (Sanchez et al., 
2008).  
Because MBPs are considered to be markers of mature oligodendrocytes, 
these findings suggested that while therapeutic levels of buprenorphine 
accelerate and promote cell differentiation, higher buprenorphine doses may 
delay oligodendrocyte maturation. It is also important to consider that opioid 
receptors are known to be ubiquitously expressed and thus, the observed 
phenotypes may not necessarily reflect a direct action of buprenorphine on the 
oligodendrocytes but could be mediated through a number of other cell types, 
including neurons and different glial populations. Therefore, these hypotheses 
raise two major questions: 
1. Does buprenorphine have any effects on oligodendrocyte 
development? 
2. Could those potential effects be attributed to direct or indirect 
actions of the drug? 
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To address these two questions, we decided to investigate the potential 
direct effects of buprenorphine on cultured oligodendrocytes. Selection of the cell 
culture system for these experiments required special considerations. 
First of all, opioid receptors are expressed throughout oligodendrocyte 
development, but previous studies have shown that their relative abundance 
changes over time (Knapp et al., 2001). In addition, oligodendrocyte progenitors, 
which are still mitotic, may respond quite differently to opioids than more mature 
pre-oligodendrocytes, the predecessors of the postmitotic and terminally 
differentiated cells capable of myelination. Therefore, it was critical that both 
progenitors and pre-oligodendrocytes be studied. Secondly, most studies on 
oligodendrocyte maturation use progenitors isolated from rodent newborn brain 
which are then cultured for several days to obtain cells at different stages of 
development. However, there is evidence to indicate that some responses may 
be lost when cells of the oligodendroglial lineage are maintained for extensive 
periods of time in purified cultures. As an example, neonatal oligodendrocytes 
become unresponsive to neurotransmitters when cultured for several days in the 
absence of neurons, losing their capacity to maintain neurotransmitter-activated 
signaling pathways coupled to Ca2+mobilization (He et al., 1996).  This becomes 
particularly important when trying to understand the molecular mechanisms that 
drive the last stages of differentiation leading to the generation of mature 
myelinating oligodendrocytes. 
For these reasons, the cultures used in these studies were prepared using 
cells directly isolated from rat brain at different postnatal ages. It is expected that 
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these cells are—at the time of plating—more representative of their in vivo 
responses than those which are induced to differentiate for extensive periods of 
time in culture. 
  Cells isolated from 3-day-old rat brain are immature oligodendrocyte 
progenitors that are either bipolar or possess several simple processes and can 
be labeled with the A2B5 antibody. On the other hand, cells obtained from 9-day-
old animals are pre-oligodendrocytes that may already be multipolar and react 
with the O4 antibody (Sato-Bigbee et al., 1999). These later cells represent a 
crucial developmental stage that immediately precedes the generation of mature 
oligodendrocytes capable of myelination. 
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TREATMENT OF OLIGODENDROCYTE PROGENITORS WITH 
BUPRENORPHINE INDUCES A DOSE-SPECIFIC STIMULATION ON CELL 
PROLIFERATION  
We found that direct exposure to buprenorphine alters the proliferative 
capacity of the oligodendrocyte progenitors. In these experiments, DNA 
synthesis was assessed by incubating the cell cultures for 24 hours in chemically 
defined medium (CDM) containing 3H-thymidine in the presence or absence of 
different concentrations of buprenorphine. As shown in Figure 5, exposure to 
buprenorphine resulted in a dose-dependent stimulation of cell proliferation, with 
maximal values of 3H-thymidine incorporation observed between 0.5µM and 
1.0µM buprenorphine. Interestingly, treatment with a higher concentration of the 
drug (3.0µM) did not yield a significant increase in oligodendrocyte proliferation 
(Figure 5). These effects seem to be mediated by the mu opioid receptor 
because a similar dose-specific stimulation of cell proliferation was observed 
when the cultures were treated with methadone, a mu-selective agonist (Figure 
6). 
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Figure 5. Exposure of oligodendrocyte progenitors to buprenorphine 
results in a dose-specific increase in cell proliferation. Oligodendrocyte 
progenitors were isolated from 3-day old rat brain as described under “Materials 
and Methods”. The cells were incubated for 24 hours in the presence or absence 
of different doses of buprenorphine. Proliferation was evaluated by 3H-thymidine 
incorporation. The results are expressed as percentage of the control values +/- 
SEM. *p<0.05. 
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Figure 6. Exposure of oligodendrocyte progenitors to methadone also 
results in a dose-specific increase in cell proliferation. Oligodendrocyte 
progenitors were isolated from 3-day old rat brain as described under “Materials 
and Methods”. The cells were incubated for 24 hours in the presence or absence 
of different doses of methadone. Proliferation was evaluated by 3H-thymidine 
incorporation. The results are expressed as percentage of the control values +/- 
SEM. *p<0.005. 
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BUPRENORPHINE ALTERS PRE-OLIGODENDROCYTE DIFFERENTIATION 
AND MORPHOLOGY 
In contrast with the observed effect on progenitor proliferation, 
buprenorphine affects the differentiation of pre-oligodendrocytes. Two 
approaches were used to assess differentiation: measuring MBP expression and 
morphological studies.  
As seen in Figure 7, oligodendrocytes isolated from 9-day old rat brain 
showed a dose-specific response in MBP production when treated with 
buprenorphine for 4 days. A maximum stimulation was observed between 
0.25µM and 0.5µM buprenorphine. Importantly, while these doses stimulated all 
four MBP isoforms, the 14 kDa isoform—predominant in mature myelin— 
showed the most significant increase. Interestingly, the maturity of the animals 
from which the cells were isolated was critical in achieving this stimulatory 
response. The increased MBP expression induced by low buprenorphine levels 
in cells from 9-day-old pups is not observed if the oligodendrocytes are instead 
isolated from 6-day-old animals (Figure 8), an observation that suggests that 
opioid signaling works in concerted action with other developmentally 
regulated mechanisms that control the last steps of oligodendrocyte 
maturation.  Moreover, in cells from the younger animals, high buprenorphine 
doses reduced MBP levels to values below those corresponding to the controls, 
a finding which as discussed later, may implicate the participation of different 
opioid receptor types.  
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Moreover, in support of an effect of buprenorphine on cell differentiation, 
we also observe a dose-specific effect on the morphology of the cells (Figure 9). 
When treated with 0.5µM buprenorphine, which, as indicated above, induces 
maximum MBP stimulation, cells show significant increases in process outgrowth 
and membrane extension. Interestingly, this effect was abolished when cells 
were treated with higher buprenorphine doses (3.0µM), which also coincides with 
lower levels of MBP in western blotting analysis. Taken together, these 
observations indicate that buprenorphine exerts a direct effect on 
oligodendrocyte maturation. 
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Figure 7. Direct treatment of pre-oligodendrocytes with buprenorphine 
alters MBP expression in a dose-specific manner. Oligodendrocytes from 9-
day-old rat brain were incubated for 4 days in CDM with or without 0.25, 0.5, 1.0, 
3.0  µM buprenorphine. MBP levels were determined by western blotting using 
beta-actin levels as loading controls. For correct quantification of individual MBP 
isoforms, film exposure times were adjusted to maintain linear detection of the 
bands. Figures correspond to representative experiments. Results in the bar 
graph are expressed as percentage of controls (0µM buprenorphine) +/- SEM. 
*p<0.02. 
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Figure 8. Direct treatment of oligodendrocytes from 6-day-old rat brain 
does not produce an increase in MBP levels. Oligodendrocytes were 
incubated for 4 days in CDM with or without 0.25, 0.5, 1.0, 3.0 µM 
buprenorphine. MBP levels were determined by western blotting using beta-actin 
levels as loading controls. For correct quantification of individual MBP isoforms, 
film exposure times were adjusted to maintain linear detection of the bands. 
Figures correspond to representative experiments. Results in the bar graph are 
expressed as percentage of controls (0µM buprenorphine) +/- SEM. *p<0.05.
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Figure 9. Buprenorphine treatment alters process network extension and 
membrane outgrowth in pre-oligodendrocytes in a dose-dependent 
manner. Oligodendrocytes isolated from 9-day old rat brain were cultured for 4 
days in CDM with or without buprenorphine (0.5µM, 3.0µM). After fixation, cells 
were stained with anti-MBP antibody and visualized by fluorescent microscopy. 
The figure shows three representative panels corresponding to each of the 
treatment conditions. Note extensive process and membrane extension in cells 
treated with 0.5µM buprenorphine. 
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BUPRENORPHINE STIMULATORY EFFECTS ON CELL DIFFERENTIATION 
ARE MEDIATED BY THE MU OPIOID RECEPTOR 
As indicated above, buprenorphine directly affects oligodendrocyte 
maturation. Because buprenorphine is both a mu partial agonist and a kappa 
antagonist, further investigation was focused on the specific receptor mediating 
these effects.  
To address the role of the mu opioid receptor in this response we used 
two approaches. First, we investigated whether or not observed buprenorphine 
effects could be mimicked by methadone, a mu opioid receptor agonist. As seen 
in Figure 10, this is indeed the case, as methadone also induces dose-specific 
effects similar to those observed with buprenorphine treatment. Moreover, both 
methadone and buprenorphine effects are abolished by co-incubation with the 
highly specific mu opioid receptor antagonist CTOP (Figure 11) further 
supporting the role of this receptor in regulating oligodendrocyte maturation.  
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Figure 10.  Direct treatment of pre-oligodendrocytes with methadone alters 
MBP expression in a dose-specific manner. Oligodendrocytes were incubated 
for 4 days in CDM with or without 0.25, 0.5, 1.0, 3.0, 5.0  µM methadone. MBP 
levels were determined by western blotting using beta-actin levels as loading 
controls. For correct quantification of individual MBP isoforms, film exposure 
times were adjusted to maintain linear detection of the bands. Figures 
correspond to representative experiments. Results in the bar graph are 
expressed as percentage of controls (0µM buprenorphine) +/- SEM.  *p<0.05. 
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Figure 11. The mu opioid receptor antagonist CTOP blocks stimulation of 
MBP by buprenorphine and methadone. Oligodendrocytes isolated from 9-day 
old rat brain were cultured for 4 days in CDM in presence or absence of 
methadone (1µM) or buprenorphine (0.5µM) with and without CTOP. MBP levels 
were determined by western blotting using beta-actin levels as loading controls. 
For correct quantification of individual MBP isoforms, film exposure times were 
adjusted to maintain linear detection of the bands. Figures correspond to 
representative experiments. Results in the bar graph are expressed as 
percentage of controls (0µM buprenorphine). 
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DISCUSSION 
Substitution therapies for opioid addiction, like those using methadone and 
buprenorphine, are valuable instruments in relieving the withdrawal associated 
with discontinuation of opioid abuse. At therapeutic doses, these synthetic 
opioids comprise the most effective tools available for substitution therapy. 
However, current understanding of their clinical efficacy is limited to the realm of 
adult opioid addicts.  
 Current clinical trials use buprenorphine to treat pregnant opioid addicts. 
Nevertheless, population studies have shown that children exposed to opioids in 
utero exhibit behavioral and cognitive deficits, suggesting that exposure to 
exogenous opioids may disrupt functions of the endogenous opioid system that 
could play a crucial role in the coordination of brain development.   
As previously described, recent results from our laboratory showed that 
perinatal exposure to buprenorphine affects myelination in the developing rat 
brain (Sanchez et al., 2008).  While exposure to therapeutic levels of 
buprenorphine resulted in accelerated and significantly increased brain levels of 
MBPs, supra-therapeutic levels retarded the appearance of these proteins and 
caused a decrease in the number of axons that were myelinated. Because MBPs 
are considered to be markers of mature oligodendrocytes, these findings 
suggested that while therapeutic levels of buprenorphine accelerate and promote 
cell differentiation, higher buprenorphine doses might delay oligodendrocyte 
maturation. However, opioid receptors are known to be ubiquitously expressed in 
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neuronal and glial populations of the CNS, making it difficult to parse out direct 
effects on any specific cell population. Thus, the reported effects of 
buprenorphine on myelination may not necessarily indicate a direct drug action 
on the oligodendrocytes. It is conceivable that buprenorphine effects on 
myelination may indirectly result from opioid actions on neurons and different 
glial populations which might then influence myelination. For this reason, it was 
important to investigate the possibility of direct effects of buprenorphine on the 
developing oligodendrocytes.  
We have now found that (1) buprenorphine indeed exerts direct actions on 
the oligodendrocytes, (2) these effects are dose-specific, and (3) the direct 
actions of the drug are highly dependent on the stage of cell differentiation.  
The present results showed that low buprenorphine doses induce 
increased proliferation of oligodendrocyte progenitors. In contrast, similar 
treatment of pre-oligodendrocytes show augmented capacity of the cells to 
synthesize MBPs and a remarkable increase in morphological complexity, both 
indicators of a stimulatory effect on oligodendrocyte maturation.  These 
buprenorphine-dependent effects on cell proliferation and differentiation are 
primarily mediated by the mu opioid receptor.  
Particularly interesting is the observation that oligodendrocyte progenitors, 
as well as pre-oligodendrocytes, exhibit a clear biphasic response to 
buprenorphine.  Our data show an increase in oligodendrocyte progenitor 
proliferation following exposure to 0.5µM- 1.0µM buprenorphine. However, when 
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progenitors are treated with 3.0µM buprenorphine, rates of DNA synthesis do not 
significantly deviate from those of untreated cells. Likewise, pre-oligodendrocytes 
exhibit increased differentiation when exposed to low concentrations of 
buprenorphine but not in response to elevated doses of the drug. Morphine 
exposure was recently shown to increase apoptotic cell death of cultured 
oligodendrocytes (Hauser et al., 2009). Thus, it is possible to hypothesize that 
our present results may be due to an effect of buprenorphine on survival. 
However, preliminary experiments in which apoptosis was detected by TUNEL 
assay revealed no marked effects that could explain observed differences 
between controls and buprenorphine-treated oligodendrocytes.    
Understanding of the molecular mechanisms underlying these effects is 
complicated by the complex pharmacology of buprenorphine. This drug is 
generally regarded as a partial mu opioid receptor agonist (Yu et al., 1997) and 
kappa opioid receptor antagonist (Leander, 1987). Additionally, buprenorphine is 
also known to bind to and activate the ORL-1 receptor (Bloms-Funke et al., 2000, 
Huang et al., 2001, Lutfy et al., 2003) and to exhibit both agonist and antagonist 
actions on delta opioid receptors (Sadee et al., 1982, Huang et al., 2001).  
Previous studies have shown that the mu opioid receptor is expressed very early 
in the oligodendroglial lineage, whereas the delta and kappa opioid receptors 
appear at later stages of development (Knapp et al., 1998). However, more 
recent analysis indicated the presence of the three opioid receptors at all stages 
along the oligodendroglial lineage (Hauser et al., 2009). Thus, it is difficult to 
ascribe responses to a particular opioid receptor signaling pathway. However, 
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our present results support the idea that the observed stimulatory actions of 
buprenorphine on the oligodendrocytes are mediated by agonist effect on the mu 
opioid receptor.  This conclusion stems from the finding that these buprenorphine 
actions could be mimicked by replacing this drug with the mu agonist methadone. 
Furthermore, we also found that buprenorphine stimulatory effects were blocked 
when oligodendrocytes were co-incubated with CTOP, a selective and potent mu 
antagonist (Gulya et al., 1988, Hawkins et al., 1989, Law and Loh, 1999).  
Previous studies showed that exposure of immature oligodendrocytes to the mu 
opioid receptor agonist PL017 resulted in elevated DNA synthesis (Knapp and 
Hauser, 1996), an observation that further supports the involvement of the mu 
opioid receptor as a mediator of the observed effects of buprenorphine on 
oligodendrocyte progenitor proliferation.  Further supporting a role for opioids in 
regulating cell proliferation in the brain, treatment of adult neuroprogenitors with 
opioid antagonists results in a marked decrease in ERK 1/2 phosphorylation and 
levels of proteins involved in cell cycling (Persson et al., 2003). Although these 
adult progenitors may differ from their neonatal counterparts, we suspect that 
ERK remains a critical element in this effect of opioid signaling as this enzyme is 
known to play an important role in the induction of oligodendrocyte progenitor 
proliferation in response to growth factor stimulation (Cui and Almazan, 2007). 
Importantly, the supposition of an in vivo role of the endogenous opioid 
system in controlling cell proliferation during CNS development is strengthened 
by the observation that synthesis of proopiomelanocortin and its processing into 
the mu and delta opioid receptor agonist beta-endorphin in the rat brain, are 
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elevated at embryonic days and postnatal ages that coincide with periods of 
crucial proliferative activity neuronal and glial progenitors (Angelogianni et al., 
2000).  Moreover, several lines of evidence support the idea that opioid signaling 
may not only be important during development but also play a role in maintaining 
adequate numbers of different cell populations in the adult brain. Treatment of 
cultured adult hippocampal progenitors with mu and delta opioid receptor 
antagonists decreases proliferation and neurogenesis (Persson et al., 2003). 
Additional work also shows that incubation with β-endorphin preferentially 
stimulates oligodendrogenesis in a population of cultured rat adult hippocampal 
progenitors (Raynor et al., 1994, Persson et al., 2006). 
 However, to our knowledge, the present study is the first to directly 
implicate the mu opioid receptor in the last stages of oligodendrocyte 
development. Direct exposure of pre-oligodendrocytes to buprenorphine not only 
stimulated MBP expression, a marker of cell maturation, but also resulted in a 
dramatic increase in process complexity and membrane outgrowth, raising the 
possibility that signaling through the mu opioid receptor plays a crucial role in 
controlling myelin formation. Moreover, this stimulation occurs in cells isolated 
from 9-day-old animals but not at earlier immediate time points of brain 
development. This later observation strongly suggests that this mu opioid 
receptor function is tightly coordinated with other developmentally controlled 
mechanisms that determine the last stage of oligodendrocyte maturation.    
Thus, this work has shown that buprenorphine has direct effects on 
oligodendrocytes, and while these cells respond uniquely according to their stage 
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of development, we also found that dosage is critically responsible for the 
biphasic response that is curiously observed in both progenitors and pre-
oligodendrocytes. Why do higher doses of buprenorphine fail to cause the 
increase in progenitor proliferation or stimulation of pre-oligodendrocyte 
differentiation that is observed when cells are treated with lower doses of this 
drug? 
One potential explanation could be receptor desensitization. However, 
several lines of evidence suggest that a biphasic response could be due to 
simultaneous activation by buprenorphine of the ORL-1 receptor. Similar to the 
bell-shape curve observed in our experiments, others have shown that while 
lower doses of buprenorphine exert an analgesic effect, this antinociceptive 
action is significantly decreased by higher levels of the drug (Dum and Herz, 
1981, Lizasoain et al., 1991). Later investigations also showed that while 
antinociception induced by buprenorphine is mediated by the mu opioid receptor, 
this effect is counteracted by the concomitant activation of ORL-1 receptors 
(Lutfy et al., 2003). In those studies, the co-administration of J-113397, an ORL-1 
receptor antagonist, not only enhanced the antinociceptive effect of 
buprenorphine but also eliminated the characteristic bell-shape response. 
Moreover, the biphasic response was not observed in ORL-1 knockout mice. We 
have found that developing oligodendrocytes express ORL-1 (unpublished 
observations), although the potential role of this receptor in these cells has never 
been investigated before.   However, it is tempting to hypothesize that while low 
doses of buprenorphine are able to activate the high affinity mu opioid receptor, 
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stimulating cell proliferation and differentiation, higher doses of the drug may 
counteract these effects by activation of ORL-1. It remains to be determined 
whether this type of dose-specific receptor activation may be responsible for the 
biphasic response of the oligodendrocyte cultures investigated in this thesis as 
well as our dose-dependent observations regarding MBP expression and 
myelination in our previous in vivo studies (Sanchez et al., 2008).    
It is important to consider that the in vivo effects of buprenorphine on 
myelination may not be entirely explained by the direct effects of buprenorphine 
that we have now found on oligodendrocytes in vitro.  There are several factors 
that confound any causative associations. First, as discussed above, dosage has 
been a critical element in each of the observed result. In vivo doses are 
measured in mg/kg/day without exact knowledge of the actual buprenorphine 
concentration in the CNS extracellular space, whereas cultures are maintained at 
a specific buprenorphine dose. In cultured oligodendrocytes, responses to 
buprenorphine vary based on the developmental state of the cells-- low doses of 
buprenorphine stimulate proliferation in progenitors, and differentiation in pre-
oligodendrocytes. However, perinatal exposure to buprenorphine affects 
oligodendrocytes throughout their maturation. Responses to opioids vary 
temporally and because progenitor populations are maintained even in adult 
animals, effects of a specific dose on oligodendrocytes at a particular stage of 
development in vitro may not be completely predictive of in vivo effects.  
In addition, in vivo phenotypes represent a concert of responses from 
neurons and glia. The ubiquity of opioid receptors in the CNS and the necessity 
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for axon-glial signaling in developmental coordination implicate all neurons and 
glia in the observed response. Since opioids influence neural progenitor 
differentiation and physiology of mature neurons and glia, their effects should be 
considered potent and diverse throughout the developing brain. Thus, while this 
work has focused on oligodendrocyte responses to opioids in vitro, our previous 
in vivo observations may also involve buprenorphine effects on neuron-glia 
interactions. Such interactions are critical to the proper timing of myelination—
although difficult to prove, it is generally assumed that neurons signal to 
oligodendrocytes when to begin the process. In turn, oligodendrocytes control 
placement of protein complexes in the axonal membrane so that they will appose 
the nodes of Ranvier. Oligodendrocytes also control the axonal cytoskeleton and 
rates of vesicular transport (Simons and Trajkovic, 2006). When surface ligands 
and receptors bind, an array of signaling cascades are activated. Interestingly, 
some pathways have been shown to proceed through MAPK signaling which has 
previously been shown to mediate opioid effects in oligodendrocytes, suggesting 
a convergence of signaling in these developmental controls (Colognato et al., 
2002, Persson et al., 2003, Colognato et al., 2004). 
In support for an additional effect on neuron-glia interactions, we showed 
before that regardless of the dose, pups perinatally exposed to buprenorphine 
exhibited a significant increase in the caliber of the myelinated axons (Sanchez 
et al., 2008). Future studies should also focus on understanding whether 
inhibition of the kappa opioid receptor may also play role in the potential effects 
of buprenorphine on myelination. Surprisingly, these axons were characterized 
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by having a disproportionately thinner myelin sheath. These changes were also 
accompanied by increased levels of myelin associated glycoprotein (MAG), a 
molecule that has been implicated in glial-axonal communication (Yin et al., 
1998).  Exposure to therapeutic low buprenorphine doses also exhibited 
increased MAG glycosylation and interaction with the Src-family tyrosine kinase 
Fyn. Interestingly, others have implicated both MAG and Fyn as clue molecules 
potentially mediating bidirectional signals between neurons and oligodendrocytes 
(Biffiger et al., 2000).  Based on these observations we hypothesized that opioid 
signaling may indeed be part of the molecular mechanisms that coordinate 
axonal radial growth with myelination (Sanchez et al., 2008).  
Altogether, our previous and present findings suggest that interference 
with the endogenous opioid system during development may have significant 
consequences on oligodendrocyte maturation and myelination. 
Although perinatal opioid exposure is the most immediate clinical correlate 
to this study, there are indeed other areas of clinical relevance. Many psychiatric 
disorders appear during adolescence and clinical studies of these patient 
populations show that changes in white matter volume coincide with onset of 
psychopathology. Under normal conditions, the rate of myelination increases 
during adolescence (Pfefferbaum et al., 1994).  This is also a critical window for 
circuit refining and changes in the brain’s reward system. The magnitude of these 
structural and functional changes is evident both physically and behaviorally 
(Paus et al., 2008). The onset of psychotic disorders during adolescence 
underscores the plasticity and vulnerability of the brain during this period. 
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Evidence suggests that many of these disorders are associated with abnormal 
development of myelin. For example, adolescents who engage in dangerous 
behavior have increased white matter maturity in the frontal cortex (Berns et al., 
2009). Studies of white matter in psychotic patients show that pathology of 
myelin may contribute to the neurobiology of psychosis (Walterfang et al., 2005). 
Since we have shown the role of opioids in oligodendrocyte development and 
myelination, their role must be considered in these pathologies—both as a cause 
and as a possible therapy.  
In conclusion, the results obtained in this thesis project indicate that 
buprenorphine and methadone exert direct and developmentally specific effects 
on the oligodendrocytes. Together with our previous observations, the present 
findings further support an important role for opioid signaling in regulating brain 
maturation and, in particular, the generation of oligodendroglial pools, 
oligodendrocyte maturation, and myelination. These observations stress the 
need for further studies and the strict control for the use of these drugs in the 
treatment of pregnant opioid addicts. Future studies investigating the molecular 
mechanisms by which buprenorphine and methadone affect myelination and 
neuro-glial interactions should provide deeper understanding into these 
developmental processes and new strategies for the managing of pregnant 
addicts.  
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